PRX Financial Facts

Restructuring costs: 269K
Net product sales: 325.75M
See Full Income Statement

Additional paid-in capital: 298.03M
Accrued legal fees: 15.14M
See Full Balance Sheet

Par Pharmaceutical Companies Inc. (PRX) Earnings

  |   Expand Research on PRX
Next EPS Date N/A EPS Growth Rate N/A
Average EPS % Beat Rate +15.3% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS -2.7% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/2/12 Q212 $1.62$1.12 +$0.50$294.3M$291.3M N/A Details
5/8/12 Q112 $0.80$0.72 +$0.08$271.5M$230.84M N/A Details
2/28/12 Q411 $0.78$0.75 +$0.03$253.6M$230.31M N/A Details
11/2/11 Q311 $0.74$0.73 +$0.01$215.4M$309.97M N/A Details
8/3/11 Q211 $0.84$0.77 +$0.07$224.2M$216.47M N/A Details
5/5/11 Q111 $0.96$0.89 +$0.07$233M$227.77M N/A Details
2/24/11 Q410 $0.61$0.67 -$0.06$227M$210.69M N/A Details
11/3/10 Q310 $0.89$0.54 +$0.35N/AN/A N/A Details